Metformin's anticancer odyssey: Revealing multifaceted mechanisms across diverse neoplastic terrains- a critical review
Rashmi Saxena Pal, Talha Jawaid, Md. Azizur Rahman, Rakesh Kumar Verma, Pratap Kumar Patra, Sharma Vedika Vijaypal, Yogendra Pal, Rohit Upadhyay
Abstract
Metformin, initially prescribed as an oral hypoglycemic medication for type 2 diabetes, has recently gained attention for its potential anticancer effects. Its history dates to 1918, when guanidine, a component of the traditional European herb Galega officinalis , was found to reduce glycemia. This review precisely examines the mechanisms underlying Metformin's anticancer effects across various neoplastic conditions. This investigation explores the complex interactions between metformin and major signaling pathways associated with carcinogenesis, including AMP-activated protein kinase (AMPK), mTOR, and insulin-like growth factor (IGF) pathways. The review emphasizes Metformin's diverse effects on angiogenesis, inflammation, apoptosis, and cellular metabolism in cancer cells. Additionally, new data on metformin's capacity to alter the tumor microenvironment and enhance immune surveillance systems against cancer are examined. The review underscores Metformin's potential for repurposing in oncology, emphasizing its clinical relevance as an adjuvant therapy for various cancers. The review provides insightful information about the complex anticancer mechanisms of metformin by combining data from preclinical and clinical studies. These findings not only broaden our knowledge of the effects of metformin but also open new avenues for oncology research and treatment developments. • Metformin, originally a diabetes drug, shows promising anticancer effects. • It influences key cancer pathways, including AMPK, mTOR, and IGF signaling. • Metformin affects angiogenesis, inflammation, apoptosis, and tumor metabolism. • Emerging evidence suggests its role in modulating the tumor microenvironment.